Hilltop National Bank Acquires Shares of 2,683 The Clorox Company $CLX

Key Points

• Hilltop National Bank acquired 2,683 shares of The Clorox Company, valued at approximately $322,000, signaling increased institutional interest in the stock.
• Clorox recently announced a quarterly dividend of $1.24, representing a 4.0% yield, with the ex-dividend date set for October 22nd.
• Analysts set new price targets for Clorox, with the consensus price target currently at $134.08, and ratings ranging from "Buy" to "Sell".

Hilltop National Bank acquired a new stake in The Clorox Company (NYSE:CLX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,683 shares of the company's stock, valued at approximately $322,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. American National Bank & Trust raised its stake in shares of Clorox by 69.5% during the 2nd quarter. American National Bank & Trust now owns 217 shares of the company's stock valued at $26,000 after buying an additional 89 shares during the last quarter. Ransom Advisory Ltd purchased a new position in Clorox during the first quarter valued at approximately $35,000. GW&K Investment Management LLC lifted its holdings in Clorox by 239.1% in the first quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock valued at $43,000 after acquiring an additional 208 shares during the period. Roble Belko & Company Inc boosted its position in Clorox by 140.7% in the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company's stock worth $53,000 after purchasing an additional 211 shares in the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in shares of Clorox during the 1st quarter worth approximately $58,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on CLX shares. Weiss Ratings reissued a "hold (c)" rating on shares of Clorox in a report on Saturday, September 27th. Citigroup reissued a "neutral" rating and set a $135.00 target price (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Wells Fargo & Company dropped their target price on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a research report on Thursday, September 25th. UBS Group lowered their price target on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. Finally, Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus price target of $134.08.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.57% of the stock is owned by corporate insiders.

Clorox Stock Up 0.9%

NYSE CLX opened at $123.30 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37. The business's fifty day simple moving average is $122.81 and its 200-day simple moving average is $129.64. The firm has a market cap of $15.08 billion, a PE ratio of 18.91, a P/E/G ratio of 0.98 and a beta of 0.52.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.63. The firm had revenue of $1.99 billion during the quarter, compared to analysts' expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. Clorox's revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 4.0%. The ex-dividend date is Wednesday, October 22nd. Clorox's dividend payout ratio is presently 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.